AR067904A1 - Derivados de piperazina-amida - Google Patents
Derivados de piperazina-amidaInfo
- Publication number
- AR067904A1 AR067904A1 ARP080103496A ARP080103496A AR067904A1 AR 067904 A1 AR067904 A1 AR 067904A1 AR P080103496 A ARP080103496 A AR P080103496A AR P080103496 A ARP080103496 A AR P080103496A AR 067904 A1 AR067904 A1 AR 067904A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- heteroaryl
- aryl
- heterocyclyl
- fluor
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004311 liver X receptors Human genes 0.000 abstract 2
- 108090000865 liver X receptors Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Estos compuestos se fijan sobre LXR alfa y LXR beta y pueden utilizarse como medicamentos para usar para enfermedades como diabetes mellitus, alzheimer, de la piel, cáncer, HIV, antilipídico. Procesos y composiciones farmacéuticas. Reivindicacion 1: Compuestos de la formula (1) en la que X es N o CH; Y es N o CH; R1 es alquilo inferior, (alcoxi inferior)-alquilo inferior, halogeno-alquilo inferior, alquenilo inferior, cicloalquilo, cicloalquil-alquilo inferior, arilo, aril-alquilo inferior, heterociclilo, heterociclil-alquilo inferior, heteroarilo o heteroaril-alquilo inferior, en los que un cicloalquilo, arilo, heterociclilo o heteroarilo puede estar opcionalmente sustituido por 1-5 sustituyentes elegidos con independencia entre el grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluoralquilo inferior y fluor-alcoxi inferior; R2 es alquilo inferior, fluor-alquilo inferior, (alcoxi inferior)-alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, arilo, aril-alquilo inferior, heterociclilo, heterociclil-alquilo inferior, heteroarilo o heteroaril-alquilo inferior, en los que un cicloalquilo, arilo, heterociclilo o heteroarilo puede estar opcionalmente sustituido por 1-5 sustituyentes elegidos con independencia entre el grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, alcoxi inferior-carbonilo y fenilo; R3 es arilo o heteroarilo, dicho arilo o heteroarilo puede estar opcionalmente sustituido por 1-5 sustituyentes elegidos con independencia entre el grupo formado por halogeno, CN, alquilo inferior, fluor-alquilo inferior, alcoxi inferior y fluor-alcoxi inferior; R4, R5, R6, R7, R8, R9, R10 y R11 con independencia entre sí son hidrogeno o alquilo inferior, o R4 y R5 están unidos entre sí, o R6 y R7 están unidos entre sí, o R8 y R9 están unidos entre sí, o R10 y R11 están unidos entre sí, para formar un anillo junto con el átomo de carbono al que están unidos, y -R4-R5-, -R6-R7-, -R8-R9- y/o -R10-R11- es -(CH2)2-6-; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114219 | 2007-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067904A1 true AR067904A1 (es) | 2009-10-28 |
Family
ID=40298643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103496A AR067904A1 (es) | 2007-08-13 | 2008-08-11 | Derivados de piperazina-amida |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8288541B2 (es) |
| EP (1) | EP2188266B1 (es) |
| JP (1) | JP5220858B2 (es) |
| KR (1) | KR101171507B1 (es) |
| CN (2) | CN103772299A (es) |
| AR (1) | AR067904A1 (es) |
| AU (1) | AU2008288537B2 (es) |
| BR (1) | BRPI0815479A2 (es) |
| CA (1) | CA2695088C (es) |
| CL (1) | CL2008002356A1 (es) |
| ES (1) | ES2393822T3 (es) |
| MX (1) | MX2010001742A (es) |
| PE (1) | PE20090592A1 (es) |
| RU (1) | RU2454412C2 (es) |
| TW (1) | TWI364420B (es) |
| WO (1) | WO2009021868A2 (es) |
| ZA (1) | ZA201001061B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101901741B1 (ko) | 2010-09-07 | 2018-10-01 | 서울대학교산학협력단 | 세스터터핀 화합물 및 이들 물질의 용도 |
| CN103172635B (zh) * | 2011-12-21 | 2016-04-27 | 上海医药工业研究院 | 哌嗪或哌啶类化合物、其盐、中间体、制备方法及应用 |
| PL2820013T3 (pl) | 2012-03-02 | 2019-01-31 | Ralexar Therapeutics, Inc. | Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych |
| CN104780976B (zh) | 2012-08-13 | 2019-01-01 | 洛克菲勒大学 | 治疗和诊断黑素瘤 |
| SG11201601640SA (en) | 2013-09-04 | 2016-04-28 | Alexar Therapeutics Inc | Liver x receptor (lxr) modulators |
| CA2923178A1 (en) | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| CA3223869A1 (en) | 2016-09-21 | 2018-03-29 | Vectus Biosystems Limited | Compositions for the treatment of hypertension and/or fibrosis |
| JP2021504315A (ja) | 2017-11-21 | 2021-02-15 | ルジェニクス，インコーポレーテッド | 多形及びその使用 |
| US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
| US20240287032A1 (en) * | 2021-05-07 | 2024-08-29 | MBD Co., Ltd. | Novel heterocyclic compound and use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US530238A (en) * | 1894-12-04 | Guard for lathes | ||
| DK350383A (da) | 1982-08-27 | 1984-02-28 | Hoffmann La Roche | Phosphorforbindelser |
| ATE128140T1 (de) | 1989-05-18 | 1995-10-15 | Hoffmann La Roche | Phosphorverbindungen. |
| JP3204668B2 (ja) | 1991-03-15 | 2001-09-04 | エフ・ホフマン―ラ ロシユ アーゲー | キラルなホスフイン |
| US5256321A (en) | 1992-07-10 | 1993-10-26 | The Lubrizol Corporation | Grease compositions |
| CN1164232A (zh) * | 1994-09-26 | 1997-11-05 | 曾尼卡有限公司 | 作为抗血栓形成剂或抗凝血剂的氨基杂环衍生物 |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| JP2000516602A (ja) * | 1996-08-14 | 2000-12-12 | ゼネカ・リミテッド | 置換ピリミジン誘導体および薬剤としてのそれらの使用 |
| BR0311263A (pt) | 2002-05-24 | 2005-04-26 | Pharmacia Corp | Moduladores anilino receptores-x do fìgado |
| MXPA04012959A (es) * | 2002-06-29 | 2005-05-16 | Zentaris Gmbh | Arilcarbonilpiperacinas y heteroarilcarbonilpiperacinas y su uso para tratamiento de enfermedades de tumor benigno y maligno. |
| EP1599447A1 (en) * | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| FR2869904B1 (fr) * | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
| AU2005267331A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| DE102005000666B3 (de) * | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2681809C (en) * | 2007-03-30 | 2012-06-05 | F. Hoffmann-La Roche Ag | Imidazolidinone derivatives |
-
2008
- 2008-08-04 BR BRPI0815479-1A2A patent/BRPI0815479A2/pt not_active IP Right Cessation
- 2008-08-04 MX MX2010001742A patent/MX2010001742A/es active IP Right Grant
- 2008-08-04 CA CA2695088A patent/CA2695088C/en not_active Expired - Fee Related
- 2008-08-04 CN CN201410037876.3A patent/CN103772299A/zh active Pending
- 2008-08-04 RU RU2010108943/04A patent/RU2454412C2/ru not_active IP Right Cessation
- 2008-08-04 WO PCT/EP2008/060213 patent/WO2009021868A2/en not_active Ceased
- 2008-08-04 AU AU2008288537A patent/AU2008288537B2/en not_active Ceased
- 2008-08-04 ES ES08786826T patent/ES2393822T3/es active Active
- 2008-08-04 CN CN200880103083.XA patent/CN101778831B/zh not_active Expired - Fee Related
- 2008-08-04 EP EP08786826A patent/EP2188266B1/en not_active Not-in-force
- 2008-08-04 JP JP2010520529A patent/JP5220858B2/ja not_active Expired - Fee Related
- 2008-08-04 KR KR1020107005485A patent/KR101171507B1/ko not_active Expired - Fee Related
- 2008-08-06 US US12/186,555 patent/US8288541B2/en not_active Expired - Fee Related
- 2008-08-11 CL CL2008002356A patent/CL2008002356A1/es unknown
- 2008-08-11 AR ARP080103496A patent/AR067904A1/es not_active Application Discontinuation
- 2008-08-11 PE PE2008001361A patent/PE20090592A1/es not_active Application Discontinuation
- 2008-08-12 TW TW097130742A patent/TWI364420B/zh active
-
2010
- 2010-02-12 ZA ZA2010/01061A patent/ZA201001061B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010535834A (ja) | 2010-11-25 |
| RU2010108943A (ru) | 2011-09-20 |
| US8288541B2 (en) | 2012-10-16 |
| AU2008288537A1 (en) | 2009-02-19 |
| CN101778831A (zh) | 2010-07-14 |
| US20090048264A1 (en) | 2009-02-19 |
| ES2393822T3 (es) | 2012-12-28 |
| EP2188266B1 (en) | 2012-10-17 |
| CN103772299A (zh) | 2014-05-07 |
| JP5220858B2 (ja) | 2013-06-26 |
| CA2695088A1 (en) | 2009-02-19 |
| TWI364420B (en) | 2012-05-21 |
| PE20090592A1 (es) | 2009-05-03 |
| RU2454412C2 (ru) | 2012-06-27 |
| CN101778831B (zh) | 2014-08-20 |
| TW200916463A (en) | 2009-04-16 |
| CL2008002356A1 (es) | 2009-05-29 |
| MX2010001742A (es) | 2010-03-10 |
| KR101171507B1 (ko) | 2012-08-07 |
| CA2695088C (en) | 2013-03-12 |
| WO2009021868A3 (en) | 2009-04-09 |
| ZA201001061B (en) | 2010-11-24 |
| KR20100043096A (ko) | 2010-04-27 |
| AU2008288537B2 (en) | 2011-03-24 |
| EP2188266A2 (en) | 2010-05-26 |
| WO2009021868A2 (en) | 2009-02-19 |
| BRPI0815479A2 (pt) | 2015-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067904A1 (es) | Derivados de piperazina-amida | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR012825A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos | |
| CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
| PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| ECSP055636A (es) | Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa | |
| UY28578A1 (es) | Derivados de amida | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| BR112014014909A2 (pt) | agonistas de tgr5 não sistêmicos | |
| DOP2015000169A (es) | Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |